Kathmandu, Nepal’s drug regulatory authority has halted the sale and distribution of an antibiotic injection, Biotax 1gm, produced by Indian pharmaceutical company Zydus Healthcare Ltd, due to significant health risks identified during inspections.

According to Kashmir Media Service, the Department of Drug Administration (DDA) in Nepal took action after discovering that Biotax 1gm did not meet production specifications, which could potentially endanger patient health. The drug, commonly used to treat bacterial infections and prevent surgical infections, failed to pass laboratory standards necessary for safe use. As a result, the DDA has instructed the manufacturer, as well as importers and distributors, to cease the sale, import, and distribution of the medication immediately. The Kathmandu Post quoted Pramod KC, spokesperson for the department, stating that the investigation into these issues is ongoing and further decisions will be announced upon its conclusion. This incident highlights ongoing concerns regarding the quality of pharmaceutical products imported from India.

The post Nepal Suspends Sale of Indian-Made Antibiotic Citing Health Risks appeared first on pakistannewsgazette.com.